SCHEMBL7051159

SCHEMBL7051159

NNC(=O)c1ncccc1Br

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 4/20 0.52
ALDH1A1 P00352 5/20 0.46
KDM4E B2RXH2 5/20 0.46
NPC1 O15118 2/20 0.46
EGLN2 Q96KS0 1/20 0.46
FTO Q9C0B1 1/20 0.46
TLR7 Q9NYK1 2/20 0.44
GAA P10253 3/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
HCRTR1 O43613 1/20 0.41
CYP3A4 P08684 2/20 0.41
CYP1A2 P05177 2/20 0.41
OGG1 O15527 1/20 0.41
MPO P05164 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2A6 P11509 1/20 0.41
CYP2C19 P33261 1/20 0.41
MAPT P10636 3/20 0.40
ALOX15 P16050 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27780749 0.85 TLR7 (0.46) ALDH1A1KDM4ENPC1EGLN2FTO
SCHEMBL109257 0.83 FTO (0.65) P2RX7ALDH1A1KDM4EEGLN2FTO
SCHEMBL20406114 0.81 PLK1 (0.45) P2RX7ALDH1A1KDM4ENPC1EGLN2
Hydrochloric Acid SCHEMBL10711160 0.80 EGLN2 (0.47) ALDH1A1KDM4EEGLN2FTOTLR7
SCHEMBL4915812 0.79 P2RX7 (0.66) P2RX7ALDH1A1KDM4EEGLN2FTO
SCHEMBL27212635 0.79 GRM4 (0.55) P2RX7ALDH1A1KDM4EEGLN2FTO
SCHEMBL518833 0.79 KDM4E (0.44) ALDH1A1KDM4EEGLN2FTOTLR7
SCHEMBL10707072 0.78 EGLN2 (0.51) ALDH1A1KDM4EEGLN2FTOTLR7
SCHEMBL8866011 0.78 KDM4E (0.47) ALDH1A1KDM4ENPC1EGLN2FTO
SCHEMBL111380 0.78 P2RX7 (0.52) P2RX7ALDH1A1KDM4EEGLN2FTO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11149040-B2 Fused triazole agonists of the APJ receptor AMGEN INC. (US) 2021-10-19 US disclosed
US-20200308189-A1 FUSED TRIAZOLE AGONISTS OF THE APJ RECEPTOR AMGEN INC. (US) 2020-10-01 US disclosed
EP-3704122-A1 FUSED TRIAZOLE AGONISTS OF THE APJ RECEPTOR Amgen Inc. (US) 2020-09-09 EP disclosed
CN-102015699-A Heterocyclic urea derivatives and methods of use thereof-211 ASTRAZENECA AB 2011-04-13 CN disclosed
WO-2004110351-A2 HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS ANADYS PHARMACEUTICALS, INC. (US) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200308189-A1 FUSED TRIAZOLE AGONISTS OF THE APJ RECEPTOR TBXA2R, AP3M1, GPBAR1 P2RX7 225/4885ALDH1A1 2156/4885KDM4E 4641/4885
US-11149040-B2 Fused triazole agonists of the APJ receptor TBXA2R, AP3M1, GPBAR1 P2RX7 225/4885ALDH1A1 2156/4885KDM4E 4641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.